Abstract
There are limited pediatric population pharmacokinetic data for voriconazole dosing, particularly in younger children. In a cohort of 34 patients younger than 3 years receiving voriconazole, the majority (n = 23, 68%) had a low initial serum concentration <1 mg/L. Among 23 children <2 years old, 19 (83%) had an initial trough <1 mg/L. There was large intra- and interindividual variability in trough levels. Dosing also varied from 3.3 to 19.6 mg/kg per dose. Only 2 of 34 patients had a documented adverse drug reaction attributable to voriconazole. More data are needed to establish optimal dosing in very young children.
MeSH terms
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / adverse effects
-
Antifungal Agents / pharmacokinetics*
-
Antineoplastic Agents / therapeutic use*
-
Child, Preschool
-
Female
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Immunocompromised Host*
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / immunology
-
Leukemia, Myeloid, Acute / therapy*
-
Male
-
Mycoses / prevention & control*
-
Myelodysplastic Syndromes / drug therapy
-
Myelodysplastic Syndromes / immunology
-
Myelodysplastic Syndromes / therapy*
-
Retrospective Studies
-
Voriconazole / administration & dosage*
-
Voriconazole / adverse effects
-
Voriconazole / pharmacokinetics*
Substances
-
Antifungal Agents
-
Antineoplastic Agents
-
Voriconazole